Obesity Drugs Lower Blood Pressure Mostly by Shedding Pounds, Landmark Analysis Finds

The blockbuster weight-loss drugs that have transformed the treatment of obesity may owe much of their blood-pressure-lowering power to the pounds patients shed while taking them, according to a sweeping new analysis of phase 3 clinical trials. The study, published in eClinicalMedicine, pooled data from 37 randomized controlled trials of glucagon-like peptide-1 receptor agonists, known as GLP-1RAs, and newer multi-hormone receptor modulators, or MHRMs, encompassing more than 50,000 adults with overweight or obesity. Its central finding is strikingly quantitative: roughly 76 percent of the variation in blood-pressure reduction across trials could be explained by differences in weight loss alone, with each percentage point of body weight lost corresponding to a fall of about 0.37 millimetres of mercury in systolic pressure.

The implications reach well beyond the obesity clinic. Systolic blood pressure, the force blood exerts against artery walls when the heart contracts, is among the most powerful modifiable predictors of heart attack, stroke and premature death. For decades, clinicians have observed that losing weight lowers blood pressure, but the evidence base was built largely on lifestyle interventions that produced modest, hard-to-sustain reductions. The 2003 meta-analysis by Neter and colleagues, drawing on 25 trials and fewer than 5,000 participants, estimated that each kilogram lost yielded roughly 1 mmHg of systolic improvement. The new analysis updates that relationship for an era in which a single weekly injection can strip away 10 to 20 percent of body weight, approaching the results of bariatric surgery.

The researchers, led by Massimo Nardone and Marcel Muskiet, systematically searched MEDLINE, Embase and Cochrane databases through December 2025, screening more than 2,000 records to identify eligible trials. To qualify, studies had to be phase 3, randomized and placebo-controlled, enrolling adults with a body mass index of at least 30, or at least 27 with a weight-related comorbidity such as hypertension or sleep apnea. Crucially, the trials had to be designed for obesity treatment rather than glucose control, ensuring the analysis captured the drugs as they are actually deployed in weight management. The final dataset spanned liraglutide, semaglutide, tirzepatide, CagriSema, orforglipron, mazdutide and ecnoglutide, with median treatment duration of 68 weeks.

The pooled results were unambiguous. Across all trials, active treatment produced a placebo-adjusted weight loss of 10.1 percent and a systolic blood-pressure reduction of 4.9 mmHg. Heterogeneity between trials was substantial, but the meta-regression showed that most of it traced back to a single variable: how much weight participants actually lost. Trials in which patients shed less than 5 percent of body weight saw systolic pressure fall by only 3.1 mmHg, while those achieving 10 to 15 percent weight loss recorded drops of 5.4 mmHg. Most dramatic were trials exceeding 15 percent weight loss, where systolic pressure fell by an average of 8.1 mmHg, a figure that approaches the lower end of what standard antihypertensive monotherapy achieves.

That benchmark matters. A 2025 meta-analysis of more than 484 double-blind, placebo-controlled trials of conventional blood-pressure drugs, including ACE inhibitors, beta-blockers, calcium-channel blockers and diuretics, found an average systolic reduction of 8.7 mmHg. By that yardstick, the most powerful of the new obesity agents are delivering cardiovascular benefits of a comparable order of magnitude through weight loss alone. The authors calculated that matching the full effect of a standard antihypertensive drug would require roughly 23 percent weight loss, a target within sight of next-generation therapies such as retatrutide, which is currently in phase 3 testing.

Not every drug behaved identically, however. Tirzepatide, which engages both the GLP-1 and GIP receptors, produced the largest blood-pressure reduction at 7.1 mmHg alongside 14.9 percent weight loss, while mazdutide achieved 6.4 mmHg. CagriSema, the amylin-GLP-1 combination that produced nearly 14 percent weight loss, yielded a comparatively smaller 5.5 mmHg reduction, and phase 2 studies of cagrilintide alone showed meaningful weight loss without significant blood-pressure benefit. These discrepancies hint that receptor-specific biology, involving pathways such as GIP, glucagon and amylin signalling, may modulate the hemodynamic effects of these drugs in ways that are not yet understood, sometimes amplifying and sometimes potentially blunting the benefits of weight reduction.

Diabetes status also shaped the response. Trials enrolling participants without type 2 diabetes recorded greater weight loss, 11.1 percent versus 6.6 percent, and larger blood-pressure reductions, 5.4 versus 3.5 mmHg, than those enrolling people with diabetes. Yet the direction of effect was consistent in both groups, and baseline blood pressure itself did not materially modify the response, countering earlier suggestions of a floor effect at lower starting pressures. The authors note that patients with diabetes often take medications and have metabolic profiles that blunt weight loss, which likely explains much of the difference.

Intriguingly, the true cardiovascular impact of these drugs may be even larger than the headline numbers suggest. Several trials reported that participants on active treatment reduced or stopped their background antihypertensive medications during follow-up, which would narrow the measured gap between drug and placebo. A participant-level analysis of three STEP trials of semaglutide found twice the rate of antihypertensive de-escalation compared with controls, and mediation analyses suggested that nearly 89 percent of the observed systolic reduction was mediated by weight loss. In the REDEFINE-1 trial of CagriSema, roughly 40 percent of participants on blood-pressure medication either reduced or discontinued it. The measured 4.9 mmHg average may therefore understate the drugs’ intrinsic effect.

Mechanistically, the findings reinforce that shrinking adipose tissue is the dominant driver of blood-pressure improvement, acting through improved insulin sensitivity, reduced sympathetic nervous system activation, enhanced sodium excretion by the kidneys and favourable effects on vascular function. But they do not rule out weight-independent actions. GLP-1 receptors are expressed in the kidney and vasculature, and mechanistic studies have documented direct GLP-1-mediated natriuresis, improved endothelial function and reduced arterial stiffness. The example of albiglutide, which conferred cardiovascular benefit despite minimal weight loss and little blood-pressure reduction, is a reminder that the cardiovascular pharmacology of this class is not reducible to the bathroom scale alone.

The study has limitations the authors acknowledge. The analysis operated at the trial level rather than the individual level, leaving it vulnerable to ecological bias and unable to adjust for patient-specific confounders. Blood pressure was not a primary endpoint in any of the included trials, and measurements came predominantly from office visits rather than ambulatory monitoring. Thirty-six of the 37 trials were judged at low risk of bias, and sensitivity analyses excluding the one high-risk trial left the core relationship essentially unchanged. Even so, the authors caution that the association describes treatment effects across studies, not a causal chain within any individual patient. What the analysis does establish, with unusual precision, is that in the era of potent obesity pharmacotherapy, weight loss has re-emerged as a first-order lever for blood-pressure control, one that international guidelines now formally endorse and that clinicians treating the roughly half of hypertensive adults who also live with obesity can no longer afford to treat as an afterthought.

Subject of Research: The relationship between weight loss and blood pressure reduction with GLP-1 receptor agonists and multi-hormone receptor modulators in adults with overweight or obesity

Article Title: Weight loss and blood pressure lowering with GLP-1 receptor agonists and multi-hormone receptor modulators in overweight and obesity: a systematic review and meta-regression of phase 3 clinical trials

Article References: Nardone, M., Kugathasan, L., Daunt, L., Parikh, E. J., River Zhang, H.-Y., Pasricha, S. V., Orchanian-Cheff, A., Cherney, D. Z., Odutayo, A., & Muskiet, M. H. (2026). Weight loss and blood pressure lowering with GLP-1 receptor agonists and multi-hormone receptor modulators in overweight and obesity: a systematic review and meta-regression of phase 3 clinical trials. eClinicalMedicine, 101, Article 104251. https://doi.org/10.1016/j.eclinm.2026.104251

Image Credits: AI Generated

DOI: 10.1016/j.eclinm.2026.104251

Keywords: obesity, hypertension, GLP-1 receptor agonists, multi-hormone receptor modulators, semaglutide, tirzepatide, weight loss, systolic blood pressure, meta-analysis, cardiovascular risk, pharmacotherapy, eClinicalMedicine